Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Immunotherapies have revolutionized cancer treatment, yet tools for monitoring immune activation in vivo remain limited. This pilot study investigates the potential of [18F]F-AraG PET to visualize activated T-cell dynamics and to assess the immunomodulatory effects of the STING agonist GSK3745417 ± PD-1 inhibitor dostarlimab. Four patients with advanced solid tumors underwent Baseline [18F]FDG PET/CT, tumor biopsy and [18F]F-AraG PET.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.